Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression

Pathology and Oncology Research

Volumn 5, Issue 3, 1999, Pages 218-222

  Bánfalvi, Teodóra ^a   Gilde, Katalin ^a   Boldizsár, Mariann ^a   Kremmer, Tibor ^a   Ottó, Szabolcs ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

5 S cysteinyldopa; Melanoma; S 100 protein

Indexed keywords

CYSTEINYLDOPA; PROTEIN S 100; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER STAGING; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE METASTASIS; MELANOMA; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 0345363240     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1053/paor.1999.0218     Document Type: Article

References (26)

1. Agrup G, Agrup P, Andersson T. 5 years experience of 5-S-cysteinyldopa in melanoma diagnosis. Acta Dermatovener (Stockholm). 59:1979;381-388.
2. Benathan M. Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cells. Melanoma Res. 6:1996;183-189.
3. Bonfrer J M, Korse C M, Israels S P. Serum S-100 has prognostic significance in malignant melanoma. Anticancer Res. 17:1997;2975-2977.
4. Buer J, Probst M, Franzke A. Elevated serum levels of S-100 and survival in metastatic malignant melanoma. Br J Cancer. 75:1997;1373-1376.
5. Cho K, Hashimoto K, Taniguchi Y. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunit. Cancer. 66:1990;765-771.
6. Fagnart C O, Sindic M J, Laterre C H. Particle counting immunassay of S-100 protein in serum. Possible relevance in tumours and ischemic disorders of the central nervous system. Clin Chem. 34:1988;1387-1391.
7. Gaynor R, Irie R, Morton D. S-100 protein is present in cultured human malignant melanomas. Nature. 286:1980;400-401.
8. Gaynor R, Irie R, Morton D. S-100 protein: A marker for human malignant melanoma? Lancet. 18:1981;869-871.
9. Guo H B, Stoffel-Wagner B, Bierwirth T. Clinical significance of serum S-100 in metastatic malignant melanoma. Eur J Cancer. 31:1995;1898-1902.
10. Hanson L O, Schoultz E, Djuren E. Prognostic value of serum analyses of S-100 protein beta in malignant melanoma. Anticancer Res. 17:1997;3071-3073.
11. Hasegawa M, Takata M, Hatta N. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res. 7:1997;243-251.
12. Henze G, Dummer R, Joller-Jemelka H. Serum S-100 - a marker for disease monitoring in metastatic melanoma. Dermatology. 194:1997;208-212.
13. Hirai S, Kageshita T, Kimura T. Serum levels of s-ICAM, and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res. 7:1997;58-62.
14. Horikoshi T, Ito S H, Wakamatsu K. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer. 73:1994;629-636.
15. Kagedal B, Pettersson A. Determination of urinary 5-S-cysteinyldopa by high performance liqiud chromatography. Chromatogr. 272:1983;287-297.
16. Ketcham A S, Moffat F L, Balch C M. Classification and staging. CM Balch Cutaneous melanoma Philadelphia, JB Lippincott. 1992;213-220.
17. Meyerhoffer S, Lindberg Z, Hager A. Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in children. Acta Derm Venereol. 78:1998;31-35.
18. Miliotes G, Lyman G H, Cruse C W. Evalutaiton of new putative tumor markers for melanoma. Ann Surg Oncol. 3:1996;558-563.
19. Nakajima T, Watanabe S, Sato Y. Immunohistochemical demonstration of S-100 protein in malignant melanoma and pigmented nevus and its diagnostic application. Cancer. 50:1982;912-918.
20. Nyberg L, Kroon L, Ullen A. Sangtec LIA a new sensitive monoclonal assay for measuring protein S 100 in patients with malignant melanoma. 1996;Final Program and Abstract Book of the XXIV Meeting of ISOBM. San Diego.
21. Peterson L, Woodward W, Fletcher W. Plasma 5-S-cysteinyldopa differentietes patients with primary and metastatic melanoma from patients with dysplasticus naevus syndroma and normal subjects. J Am Acad Dermatol. 19:1988;509-515.
22. Schoultz E, Hansson L O, Djureen E. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res. 6:1996;133-137.
23. Schoultz E S, Diepgen T L, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 beta protein in malignant melanoma. Br J Dermatol. 138:1998;426-430.
24. Sasaki Y, Shimizu H, Naka W. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years experience of 50 patients. Acta Derm Venerol. 77:1998;379-381.
25. Wakamatsu K, Ito S. Seasonal variations in serum concentration of 5-S- cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxyl acid in healthy Japanese. Pigment Cell Res. 8:1995;132-134.
26. Wimmer I, Meyer C J, Seifert B. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemoterapy. Cancer Res. 57:1997;5073-5076.